Aller au contenu principal
Accès ouvert déclaré 2021 article

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

5Citations signalées, ce qui n’est pas une note de qualité
102Institutions déclarées
18Pays d’affiliation déclarés

Rattachement africain : nl, au, us, de, se, ru, dk, gb, es, no, fi, fr, pl, be, gr, it, il, cy. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Breast cancer metastasis accounts for most of the deaths from breast cancer. Identification of germline variants associated with survival in aggressive types of breast cancer may inform understanding of breast cancer progression and assist treatment. In this analysis, we studied the associations between germline variants and breast cancer survival for patients with distant metastases at primary breast cancer diagnosis. We used data from the Breast Cancer Association Consortium (BCAC) including 1062 women of European ancestry with metastatic breast cancer, 606 of whom died of breast cancer. We identified two germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific survival (P = 3.19 × 10−8 and 4.42 × 10−8). In silico analysis suggested a potential regulatory effect of the variants on the nearby target genes SDE2 and H3F3A. However, the variants showed no evidence of association in a smaller replication dataset. The validation dataset was obtained from the SNPs to Risk of Metastasis (StoRM) study and included 293 patients with metastatic primary breast cancer at diagnosis. Ultimately, larger replication studies are needed to confirm the identified associations.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis
Date Crossref
05/10/2021
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

The Netherlands Cancer InstituteNetherlands Cancer Institute-Antoni van Leeuwenhoek HospitalQIMR Berghofer Medical Research InstituteUniversity of California, IrvineGerman Cancer Research CenterHeidelberg UniversityLund UniversityUniversität HamburgUniversity Medical Center Hamburg-EppendorfUniversitätsklinikum ErlangenComprehensive Cancer Center ErlangenUfa Institute of ChemistryUniversity of CopenhagenHerlev HospitalCopenhagen University HospitalGentofte HospitalUniversity of CambridgeNational Center for Tumor DiseasesDeutsches Konsortium für Translationale KrebsforschungServicio Gallego de SaludUniversity Cancer Center HamburgNational Institutes of HealthNational Cancer InstituteMayo Clinic in ArizonaKarolinska InstitutetFox Chase Cancer CenterLeiden University Medical CenterMedizinische Hochschule HannoverCancer Research UK Cambridge CenterBrigham and Women's HospitalHarvard UniversityUniversity of California, Los AngelesUniversity of California San DiegoComplejo Hospitalario Universitario de SantiagoFundación Pública Galega de Medicina XenómicaInstituto de Investigación Sanitaria de SantiagoHospital Clínico San CarlosInstituto de Investigación Sanitaria del Hospital Clínico San CarlosCentro de Investigación Biomédica en Red de CáncerAkershus University HospitalThe University of MelbourneCancer Council VictoriaMonash HealthMonash UniversityOulu University HospitalUniversity of OuluHelmholtz MunichGerman Center for Diabetes ResearchUniversity of CologneUniversity Hospital CologneUniversity of Southern CaliforniaStockholm South General HospitalUniversity of Eastern FinlandErasmus MC Cancer InstituteDr. Margarete Fischer-Bosch-Institute of Clinical PharmacologyUniversity of TübingenUniversity of OxfordUniversité de MontpellierInstitut de Recherche en Cancérologie de MontpellierPomeranian Medical UniversityStanford Cancer InstituteStanford UniversityBashkir State UniversityOslo University HospitalUniversity of OsloVIB-KU Leuven Center for Cancer BiologyKU LeuvenUniversity of Hawaiʻi at MānoaUniversity of Hawaii SystemCancer Center of HawaiiUniversity of Hawaii Cancer CenterKarolinska University HospitalMoorfields Eye Hospital NHS Foundation TrustMRC Epidemiology UnitUniversity College LondonMedical Research CouncilKuopio University HospitalUniversity Hospital of HeraklionUniversity of HelsinkiHelsinki University HospitalUniversity of North Carolina at Chapel HillAmerican Cancer SocietyIFOMFondazione IRCCS Istituto Nazionale dei TumoriCarmel Medical CenterHospital Universitario Puerta de Hierro MajadahondaStädtisches Klinikum KarlsruheUniversity Hospital of LarissaKing's College LondonLondon CancerInstitute of Cancer ResearchMayo Clinic in FloridaCornell UniversityWeill Cornell MedicineLyon 1 UniversitéCentre de Recherche en Cancérologie de LyonCentre for Human GeneticsUniversity of BirminghamNordLabUppsala UniversityCyprus Institute of Neurology and GeneticsCentre Léon Bérard

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cancer Genomics and DiagnosticsBRCA gene mutations in cancerEpigenetics and DNA Methylation

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.